      1 citigroups
      5 slid
      3 recommend
      2 hybrids
<<CONTENT>>
astrazeneca hit by drug failure

shares in angloswedish drug have closed down 8% in uk trade after the failure of its iressa drug in a major clinical trial

the lung cancer drug did not significantly prolong survival in patients with the disease this setback for the group follows the rejection by the us in october of its anticoagulant pill exanta meanwhile another of its major money spinners  cholesterol drug crestor  is facing mounting safety concerns this would be two of the three blockbuster drugs that were meant to power the company forward failing and weve got risks on crestor said nick turner analyst at brokers jefferies

astrazeneca had hoped to pitch its iressa drug against rival medicine tarceva but iressa proved no better than a placebo in extending lives in the trial involving 1692 patients tarceva  made by osi pharmaceuticals genentech and roche  has already proved to be successful in helping prolong the life of lung cancer patients aztrazeneca has now appointed a new executive director to the board john patterson will be in charge of drug development the company said mr patterson would make substantial changes to the clinical organisation and its processes i am determined to improve our development and regulatory performance restore confidence in the company and value to shareholders said chief executive tom mckillop
